Skip to main content
Top
Published in: Medical Oncology 4/2010

01-12-2010 | Original Paper

VEGF −460C>T polymorphism and cancer risk: a meta-analysis

Authors: Bin Xu, Ning-Han Feng, Na Tong, Zi-Dun Wang, Wei Zhang, Hong-Fei Wu, Lin-Xin Hua

Published in: Medical Oncology | Issue 4/2010

Login to get access

Abstract

Vascular endothelial growth factor (VEGF) is a major driver of physiological and pathological angiogenesis and plays important roles in the etiology and metastasis of cancers. The −460C>T polymorphism in VEGF gene region has been implicated in cancer risk and related to VEGF expression. However, published data remain conflicting. To derive a more precise estimation, a meta-analysis of 5,863 cases and 5,276 controls from 14 published case–control studies was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association. VEGF −460T represented a risk factor for cancers in Asians (OR = 1.69, 95% CI: 1.09–2.62) but not in Europeans (OR = 0.92, 95% CI: 0.78–1.08). Our meta-analysis showed the evidence that VEGF −460T was associated with increased cancer risk in Asians. Further prospective researches with larger numbers of worldwide participants are expected to validate this result.
Literature
1.
go back to reference Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 2000;19:6122–9.PubMedCrossRef Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 2000;19:6122–9.PubMedCrossRef
2.
go back to reference Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 1997;157:2323–8.PubMedCrossRef Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 1997;157:2323–8.PubMedCrossRef
3.
go back to reference Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550–63.PubMedCrossRef Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65:550–63.PubMedCrossRef
4.
go back to reference Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93:1493–5.PubMed Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93:1493–5.PubMed
5.
go back to reference Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812–6.PubMed Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812–6.PubMed
6.
go back to reference Amano M, Yoshida S, Kennedy S, et al. Association study of vascular endothelial growth factor gene polymorphisms in endometrial carcinomas in a Japanese population. Eur J Gynaecol Oncol. 2008;29:333–7.PubMed Amano M, Yoshida S, Kennedy S, et al. Association study of vascular endothelial growth factor gene polymorphisms in endometrial carcinomas in a Japanese population. Eur J Gynaecol Oncol. 2008;29:333–7.PubMed
7.
go back to reference Cacev T, Loncar B, Seiwerth S, et al. Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 2008;27:569–74.PubMedCrossRef Cacev T, Loncar B, Seiwerth S, et al. Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 2008;27:569–74.PubMedCrossRef
8.
go back to reference Chae YS, Kim JG, Sohn SK, et al. Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology. 2006;71:266–72.PubMedCrossRef Chae YS, Kim JG, Sohn SK, et al. Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology. 2006;71:266–72.PubMedCrossRef
9.
go back to reference Dassoulas K, Gazouli M, Rizos S, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2009;48:563–9.PubMedCrossRef Dassoulas K, Gazouli M, Rizos S, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2009;48:563–9.PubMedCrossRef
10.
go back to reference Hsieh YY, Chang CC, Tsai FJ, et al. T allele for VEGF-460 gene polymorphism at 5′-untranslated region is associated with higher susceptibility of leiomyoma. Biochem Genet. 2008;46:356–61.PubMedCrossRef Hsieh YY, Chang CC, Tsai FJ, et al. T allele for VEGF-460 gene polymorphism at 5′-untranslated region is associated with higher susceptibility of leiomyoma. Biochem Genet. 2008;46:356–61.PubMedCrossRef
11.
go back to reference Konac E, Onen HI, Metindir J, et al. Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol. 2007;26:453–63.PubMedCrossRef Konac E, Onen HI, Metindir J, et al. Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol. 2007;26:453–63.PubMedCrossRef
12.
go back to reference Ku KT, Wan L, Peng HC, et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol. 2005;41:497–502.PubMedCrossRef Ku KT, Wan L, Peng HC, et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol. 2005;41:497–502.PubMedCrossRef
13.
go back to reference Lin CC, Wu HC, Tsai FJ, et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology. 2003;62:374–7.PubMedCrossRef Lin CC, Wu HC, Tsai FJ, et al. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology. 2003;62:374–7.PubMedCrossRef
14.
go back to reference Maltese P, Canestrari E, Ruzzo A, et al. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int J Colorectal Dis. 2009;24:165–70.PubMedCrossRef Maltese P, Canestrari E, Ruzzo A, et al. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int J Colorectal Dis. 2009;24:165–70.PubMedCrossRef
15.
go back to reference Onen IH, Konac E, Eroglu M, et al. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep. 2008;35:17–22.PubMedCrossRef Onen IH, Konac E, Eroglu M, et al. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep. 2008;35:17–22.PubMedCrossRef
16.
go back to reference Zhai R, Liu G, Asomaning K, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008;29:2330–4.PubMedCrossRef Zhai R, Liu G, Asomaning K, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008;29:2330–4.PubMedCrossRef
17.
go back to reference Zhai R, Liu G, Zhou W, et al. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008;14:612–7.PubMedCrossRef Zhai R, Liu G, Zhou W, et al. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res. 2008;14:612–7.PubMedCrossRef
18.
go back to reference Balasubramanian SP, Cox A, Cross SS, et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007;121:1009–16.PubMedCrossRef Balasubramanian SP, Cox A, Cross SS, et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007;121:1009–16.PubMedCrossRef
19.
go back to reference Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev. 2006;15:1148–52.PubMedCrossRef Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev. 2006;15:1148–52.PubMedCrossRef
20.
21.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
22.
go back to reference Al-Moundhri MS, Al-Nabhani M, Burney IA, et al. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-A case-control study in an Omani population. Mol Carcinog. 2009. [Epub ahead of print]. Al-Moundhri MS, Al-Nabhani M, Burney IA, et al. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms-A case-control study in an Omani population. Mol Carcinog. 2009. [Epub ahead of print].
23.
go back to reference Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000;92:1764–72.PubMedCrossRef Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000;92:1764–72.PubMedCrossRef
24.
go back to reference Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. Jama. 1998;279:281–6.PubMedCrossRef Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. Jama. 1998;279:281–6.PubMedCrossRef
25.
go back to reference Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. Jama. 1992;267:374–8.PubMedCrossRef Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. Jama. 1992;267:374–8.PubMedCrossRef
26.
go back to reference Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet. 1991;337:867–72.PubMedCrossRef Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet. 1991;337:867–72.PubMedCrossRef
Metadata
Title
VEGF −460C>T polymorphism and cancer risk: a meta-analysis
Authors
Bin Xu
Ning-Han Feng
Na Tong
Zi-Dun Wang
Wei Zhang
Hong-Fei Wu
Lin-Xin Hua
Publication date
01-12-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9329-2

Other articles of this Issue 4/2010

Medical Oncology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.